The Ministry of AYUSH and the Council of Scientific and Industrial Research (CSIR) have partnered to validate four Ayush formulations against COVID-19. The trials are expected to start within one week. The results will be given in 3 months.
The partnership is a clinical study multi-centric in different parts of the country and variable design. for this purpose, a task-force has been formed and have prepared guideline for the clinical trial
Under the move, four candidates namely Ashwagandha, Yashtimadhu (Mulethi), Guduchi + Pippali (Giloy), and AYUSH-64 will be used for the trial. These drugs were invented for the treatment of malaria. Repurposing is currently going on.
Under the partnership, a competitive study between Hydroxychloroquine and Ashwagandha has been planned.
The four formulations will be tried as an add-on therapy and standard care for COVID-19 patients.
